![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Equipment Malfunctions, Contamination Issues Nab 483 Citations for Akorn
Equipment Malfunctions, Contamination Issues Nab 483 Citations for Akorn
![WarningTape.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/WarningTape.gif?t=1576815636&width=430)
Akorn Pharmaceuticals continued drug production when equipment malfunctions would normally require it to abort the batch, the FDA said in a Form 483.
The Illinois-based company was cited for several GMP issues, including potential contamination of drug products.
Additionally, production personnel failed to reject drugs that were manufactured in a clean room that were exposed due to a fear of not meeting fill yield requirements.
Upcoming Events
-
21Oct